Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience-Reference-Cited by-同舟云学术

Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience

Published:1990-12 Issue:6 Volume:37 Page:943-950
ISSN:0960-0760
Container-title:The Journal of Steroid Biochemistry and Molecular Biology
language:en
Short-container-title:The Journal of Steroid Biochemistry and Molecular Biology

Author:

Labrie F.,Dupont A.,Cusan L.,Gomez J.,Emond J.,Monfette G.

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Endocrinology,Molecular Biology,Molecular Medicine,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference50 articles.

1. Cancer Statistics, 1990. CA-A;Silverberg;Cancer J. Clin.,1990

2. Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate;Huggins;Cancer Res.,1941

3. National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: progress report;Johnson;Cancer Treat. Rep.,1977

4. Antifertility effects of LHRH agonists in the male;Labrie;J. Androl.,1980

5. Treatment of prostate cancer with gonadotropin-releasing hormone agonists;Labrie;Endocr. Rev.,1986

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells;Prostate Cancer;2020-07-31

2. NGF/γ-IFN Inhibits Androgen-Independent Prostate Cancer and Reverses Androgen Receptor Function Through Downregulation of FGFR2 and Decrease in Cancer Stem Cells;Stem Cells and Development;2012-12-10

3. Combined androgen blockade in the management of advanced prostate cancer: A sensible or ostensible approach;International Journal of Urology;2004-12

4. Contribution of the androgen receptor to prostate cancer predisposition and progression;Cancer and Metastasis Reviews;2001

5. Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer;European Urology;1998